CY1116925T1 - Ρελαξινη για χρηση στη θεραπευτικη αγωγη της δυσπνοιας η οποια συσχετιζεται με οξεια καρδιακη ανεπαρκεια - Google Patents

Ρελαξινη για χρηση στη θεραπευτικη αγωγη της δυσπνοιας η οποια συσχετιζεται με οξεια καρδιακη ανεπαρκεια

Info

Publication number
CY1116925T1
CY1116925T1 CY20151100824T CY151100824T CY1116925T1 CY 1116925 T1 CY1116925 T1 CY 1116925T1 CY 20151100824 T CY20151100824 T CY 20151100824T CY 151100824 T CY151100824 T CY 151100824T CY 1116925 T1 CY1116925 T1 CY 1116925T1
Authority
CY
Cyprus
Prior art keywords
relaxin
acute heart
acute
heart deficiency
education
Prior art date
Application number
CY20151100824T
Other languages
English (en)
Inventor
Elaine Unemori
Sam L Teichman
Gad Cotter
Dennis R Stewart
Martha Jo Whitehouse
Original Assignee
Corthera, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corthera, Inc. filed Critical Corthera, Inc.
Publication of CY1116925T1 publication Critical patent/CY1116925T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2221Relaxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/64Relaxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η αποκάλυψη αφορά μεθόδους μείωσης ρήξης αντιρρόπησης μέσω οξείας παρέμβασης, όπου συμπεριλαμβάνονται υποκείμενα τα οποία έχουν προσβληθεί από οξεία μη αντιρροπούμενη καρδιακή ανεπάρκεια. Συγκεκριμένα, η αποκάλυψη παρέχει μεθόδους για τη θεραπευτική αγωγή οξείας καρδιακής ρήξης αντιρρόπησης δια χορήγησης μίας φαρμακευτικά αποτελεσματικής ποσότητας ρελαξίνης.
CY20151100824T 2008-05-16 2015-09-18 Ρελαξινη για χρηση στη θεραπευτικη αγωγη της δυσπνοιας η οποια συσχετιζεται με οξεια καρδιακη ανεπαρκεια CY1116925T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US19054508P 2008-08-28 2008-08-28
US20124008P 2008-12-08 2008-12-08
US16433309P 2009-03-27 2009-03-27
EP09747740.0A EP2288373B1 (en) 2008-05-16 2009-05-15 Relaxin for use in treating of dyspnea associated with acute heart failure

Publications (1)

Publication Number Publication Date
CY1116925T1 true CY1116925T1 (el) 2017-04-05

Family

ID=40834101

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100824T CY1116925T1 (el) 2008-05-16 2015-09-18 Ρελαξινη για χρηση στη θεραπευτικη αγωγη της δυσπνοιας η οποια συσχετιζεται με οξεια καρδιακη ανεπαρκεια

Country Status (30)

Country Link
US (7) US8415301B2 (el)
EP (2) EP2829280A1 (el)
JP (4) JP5651586B2 (el)
CN (3) CN106177914A (el)
AR (1) AR071810A1 (el)
AU (1) AU2009246114B2 (el)
BR (1) BRPI0913011A2 (el)
CA (1) CA2724540C (el)
CR (1) CR11749A (el)
CY (1) CY1116925T1 (el)
DK (1) DK2288373T3 (el)
EA (2) EA201500552A1 (el)
ES (1) ES2546287T3 (el)
GB (2) GB2459983B (el)
HK (5) HK1139051A1 (el)
HR (1) HRP20150845T1 (el)
HU (1) HUE025483T2 (el)
IL (3) IL208992A (el)
MA (1) MA32389B1 (el)
MX (1) MX2010012450A (el)
MY (2) MY159803A (el)
NZ (3) NZ589009A (el)
PL (1) PL2288373T3 (el)
PT (1) PT2288373E (el)
SG (2) SG191587A1 (el)
SI (1) SI2288373T1 (el)
TW (1) TWI386202B (el)
UA (1) UA99953C2 (el)
WO (1) WO2009140659A2 (el)
ZA (1) ZA201007449B (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010012502A (es) * 2008-05-16 2011-04-11 Corthera Inc Metodo para el tratamiento de insuficiencia cardiaca cronica.
PL2288373T3 (pl) * 2008-05-16 2015-11-30 Corthera Inc Relaksyna do stosowania w leczeniu duszności powiązanej z ostrą niewydolnością serca
KR101800040B1 (ko) 2010-03-10 2017-11-21 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 릴랙신을 사용한 아쿠아포린의 조절
CA2802273A1 (en) 2010-08-06 2012-02-09 Pronota N.V. Perlecan as a biomarker for renal dysfunction
WO2012024452A2 (en) 2010-08-17 2012-02-23 Ambrx, Inc. Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
KR20140054009A (ko) * 2011-07-01 2014-05-08 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신 융합 폴리펩타이드 및 그의 용도
WO2013059879A1 (en) * 2011-10-26 2013-05-02 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
CA2864100A1 (en) * 2012-02-14 2013-08-22 The Regents Of The University Of California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
WO2013165606A1 (en) 2012-05-04 2013-11-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of the relaxin receptor 1
UA117571C2 (uk) * 2012-10-26 2018-08-27 Чіесі Фармацеутічі С.П.А. Способи контролювання кров'яного тиску та зниження диспное при серцевій недостатності
SG11201508251RA (en) 2013-04-05 2015-11-27 Scpharmaceuticals Llc Pharmaceutical formulations for subcutaneous administration of furosemide
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
WO2015114593A2 (en) * 2014-02-03 2015-08-06 Novartis Ag Filters for infusion sets
EP2946788A1 (en) * 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
EP3154559B1 (en) * 2014-06-13 2021-09-01 Novartis AG Use of serelaxin to reduce gdf-15
ES2903257T3 (es) 2015-12-09 2022-03-31 Scripps Research Inst Proteínas de fusión de inmunoglobulina de relaxina y métodos de uso
EP3413783A1 (en) 2016-02-12 2018-12-19 Cardiac Pacemakers, Inc. Systems and methods for patient monitoring
BR112019016139A2 (pt) 2017-02-08 2020-04-07 Bristol-Myers Squibb Company polipeptídio de relaxina modificada compreendendo um melhorador farmacocinético e usos do mesmo
US11832970B2 (en) 2017-07-26 2023-12-05 Cardiac Pacemakers, Inc. Worsening heart failure stratification
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
EP3906019A1 (en) 2019-01-04 2021-11-10 SQ Innovation AG Pharmaceutical compositions of furosemide and uses thereof
CN113747881B (zh) 2019-01-31 2024-05-14 Sc医药品有限公司 呋塞米的浓缩液体药物制剂及其给药方法
WO2024047130A1 (en) 2022-08-31 2024-03-07 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Immunosuppressive medicament and method of treatment

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
US5478807A (en) 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
ATE241012T1 (de) 1993-06-21 2003-06-15 Genentech Inc Verfahren zur herstellung von humanen relaxin
CA2145515A1 (en) 1993-07-27 1995-02-09 Mario Bigazzi Use of relaxin as therapeutic or preventing agent
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5811395A (en) 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
AU6777196A (en) 1995-08-15 1997-03-12 Connective Therapeutics Inc. Method of promoting angiogenesis
WO2001058468A1 (en) 2000-02-09 2001-08-16 Connetics Corporation Use of relaxin to treat diseases related to vasoconstriction
DE10155843A1 (de) * 2000-11-16 2003-01-30 Immundiagnostik Ag Verfahren zur Prognose und Diagnose von Herzinsuffizienz
US20050113286A1 (en) 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
EP1729817B1 (en) 2004-03-30 2014-03-05 Industry-Academic Cooperation Foundation Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin
US20060264367A1 (en) 2005-05-21 2006-11-23 Howard Florey Institute Prevention of fibrosis following cardiac injury
TW200800206A (en) 2005-07-11 2008-01-01 Abbott Lab Methods for determining how to treat congestive heart failure
WO2009007848A2 (en) 2007-07-12 2009-01-15 Compugen Ltd. Bioactive peptides and method of using same
PL2288373T3 (pl) * 2008-05-16 2015-11-30 Corthera Inc Relaksyna do stosowania w leczeniu duszności powiązanej z ostrą niewydolnością serca
MX2010012502A (es) 2008-05-16 2011-04-11 Corthera Inc Metodo para el tratamiento de insuficiencia cardiaca cronica.

Also Published As

Publication number Publication date
NZ701038A (en) 2016-01-29
SG10201609580YA (en) 2016-12-29
US9579363B2 (en) 2017-02-28
US8415301B2 (en) 2013-04-09
IL228244A (en) 2016-10-31
JP2016053040A (ja) 2016-04-14
SI2288373T1 (sl) 2015-12-31
US20170151311A1 (en) 2017-06-01
GB2459983B (en) 2010-04-28
MY159803A (en) 2017-02-15
JP2011520918A (ja) 2011-07-21
MX2010012450A (es) 2011-03-21
US20150320834A1 (en) 2015-11-12
MY158327A (en) 2016-09-30
AR071810A1 (es) 2010-07-14
UA99953C2 (uk) 2012-10-25
HK1187550A1 (zh) 2014-04-11
JP5651586B2 (ja) 2015-01-14
GB0918132D0 (en) 2009-12-02
AU2009246114B2 (en) 2013-01-31
CR11749A (es) 2011-02-11
MA32389B1 (fr) 2011-06-01
NZ589009A (en) 2012-05-25
US20120040902A1 (en) 2012-02-16
CN102036679A (zh) 2011-04-27
CN106177914A (zh) 2016-12-07
EP2288373A2 (en) 2011-03-02
EA201001771A1 (ru) 2011-06-30
CN103212063A (zh) 2013-07-24
GB2462221B (en) 2010-09-01
GB2459983A (en) 2009-11-18
US20130116181A1 (en) 2013-05-09
JP5875646B2 (ja) 2016-03-02
US8372809B2 (en) 2013-02-12
CN103212063B (zh) 2015-07-22
WO2009140659A3 (en) 2010-07-22
NZ598709A (en) 2013-09-27
GB0908432D0 (en) 2009-06-24
BRPI0913011A2 (pt) 2019-09-03
US20120040903A1 (en) 2012-02-16
EP2829280A1 (en) 2015-01-28
EP2288373B1 (en) 2015-06-24
AU2009246114A1 (en) 2009-11-19
PL2288373T3 (pl) 2015-11-30
ES2546287T3 (es) 2015-09-22
IL208992A0 (en) 2011-01-31
HUE025483T2 (en) 2016-02-29
HRP20150845T1 (hr) 2015-11-06
JP5638044B2 (ja) 2014-12-10
CA2724540A1 (en) 2009-11-19
ZA201007449B (en) 2011-06-29
US20130210730A1 (en) 2013-08-15
IL247351A0 (en) 2016-09-29
DK2288373T3 (en) 2015-09-28
HK1140693A1 (en) 2010-10-22
HK1151229A1 (en) 2012-01-27
TW200948353A (en) 2009-12-01
TWI386202B (zh) 2013-02-21
HK1202054A1 (en) 2015-09-18
IL208992A (en) 2013-09-30
US9205132B2 (en) 2015-12-08
EA201500552A1 (ru) 2016-07-29
US20100048475A1 (en) 2010-02-25
CA2724540C (en) 2014-07-08
JP2013040174A (ja) 2013-02-28
HK1139051A1 (en) 2010-09-10
GB2462221A (en) 2010-02-03
EA022948B1 (ru) 2016-03-31
US9066916B2 (en) 2015-06-30
US8053411B2 (en) 2011-11-08
SG191587A1 (en) 2013-07-31
PT2288373E (pt) 2015-10-19
JP2015013870A (ja) 2015-01-22
WO2009140659A2 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
CY1116925T1 (el) Ρελαξινη για χρηση στη θεραπευτικη αγωγη της δυσπνοιας η οποια συσχετιζεται με οξεια καρδιακη ανεπαρκεια
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
CY1121041T1 (el) Μεθοδοι αγωγης παιδιατρικων ασθενων με τη χρηση δεξμεδετομιδινης
PH12015500407A1 (en) Methods of treating hypertriglyceridemia
MX336145B (es) Metodo para el tratamiento de insuficiencia cardiaca cronica.
BRPI0909557A2 (pt) conjunto de bandagem, sistema de tratamento com pressão reduzida e sistema para auxiliar a cura de um ferimento em uma paciente.
EA201201657A1 (ru) Лечение диабета
MX2023005455A (es) Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
MX2018008709A (es) Uso terapeutico de inhibidores de activacion o estimulacion de celulas t.
CY1116344T1 (el) Κυτταρα προερχομενα απο ιστο ομφαλιου λωρου για την θεραπεια νευροπαθητικου πονου και σπαστικοτητας
MX2016001186A (es) Diagnostico y terapia de cancer que implica celulas madre cancerosas.
EP2582682A4 (en) METHOD FOR THE TREATMENT OF LUNG DISEASES
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
PH12017500392A1 (en) Medical treatments based on anamorelin
EA201200319A1 (ru) Введение активированного угля при оказании неотложной помощи в случае передозировки этексилата дабигатрана
AU2016219717A1 (en) Treating dyspnea associated with acute heart failure with relaxin
WO2013177478A3 (en) Treatment method
EA200970292A1 (ru) Производные 5-тиоксилопиранозы и их применение в терапии
CU20100225A7 (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
UA110451C2 (en) Method for stimulating reparative processes in patients with severe periodontitis
UA109904C2 (uk) Комбінована терапія для шкірних розладів